Pangaea Oncology, S.A. (PANGAEA ONCOLOGY S.A.) Aktie

Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. It offers molecular diagnostics, such as mutation analysis in tissue and liquid biopsy, gene amplification and translocation testing, immunohistochemistry and fluorescence in-situ hybridization, and gene expression profiling; clinical trials; in vitro drug profiling, including MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx platform, which performs companion diagnostic platform validation. The company also provides biomarker discovery to improve treatment through identification of novel theranostic biomarkers. Pangaea Oncology, S.A. was incorporated in 2006 and is based in Barcelona, Spain.